ABBV
- Trade priority
- #9 · 78.4
- Data coverage
- 100%
- Setup
- pre breakout · 2026-10-02
- News
- positive w/ risks
- Next catalyst
- Earnings in 19 sessions
Trade plan
- Action
- WAITblocked: uncertain event
- Trigger
- 264.79break above resistance · 0.8% / 0.38 ATR away
- Entry zone
- 264.79–267.37reference 264.79
- Initial stop
- 259.382.0% · risk 5.41/sh
- Target 1
- 279.99+5.7% · R:R 2.81 (strong)
- Target 2
- 290.30+9.6% · R:R 4.72
- Risk per share
- 5.41strategy-owned; the portfolio panel sizes it per profile
- Invalidation
- 259.38a close below 1 ATR under the level invalidates the setup before entry
Level 264.53 (PRE_BREAKOUT_V1 selected resistance); ATR14 5.15 on 2026-10-02. Stop: 1 ATR below the breakout level 264.53. Targets: ATR projections 3 / 5 ATR above the level. R:R quality strong to T1 (hard minimum 2.0; 3R would be 281.02, T2 supports 4.72R). Targets are structural and are never moved to reach an R multiple.
Record the fill after you enter: add position. The strategy then manages the stop, targets and the next action.
Your portfolio · San
- Profile
- Sanequity 2,000.00 USD · whole shares
- Current holding
- noneno open position in this profile
- Recommended quantity
- 1 sh264.79 · 13.2% of portfolio · bound by risk budget
- Risk budget
- 10.000.5% of 2,000.00 · planned risk 5.41
- Portfolio risk
- 0.00 openremaining 40.00 → 34.59 after
- Exposure
- 0 / 3 positionsHealthcare: 0 / 2 · 0.00 of 1,000.00 cap
- Cash impact
- 2,000.00 → 1,735.21derived from the ledger
- Eligibility
- WAITsame as the strategy view
Entry, stop, targets and R:R are strategy-owned and identical for every profile; only this portfolio's quantity, risk, exposure and cash differ. Manage profiles · record a fill
Quality gates
| Gate | Verdict | Detail |
|---|---|---|
| Data freshness | PASS | 0 completed session(s) behind the calendar |
| Price | PASS | close 262.82 at or above the 10 floor |
| Market cap | PASS | market cap 459.33B (finnhub, 2026-10-02) |
| Liquidity | PASS | ADV20 1115.8M (STRONG_LIQUIDITY) |
| Sector | PASS | sector Healthcare (finnhub_industry) |
| Regime | PASS | regime RISK_ON |
| Earnings | PASS | earnings in 19 sessions (2026-10-30) |
| News / event risk | FAIL | HIGH-materiality event with unknown direction · uncertain event |
| Chase protection | PASS | 0.20 ATR above EMA20, session move 0.56 ATR |
| R:R | PASS | reward/risk 2.81 to target 1 (strong), 4.72 to target 2 |
| Portfolio capacity | PASS | 1 shares (265), bound by risk budget |
| Data quality | PASS | current session data, valid technical snapshot, trigger and ATR; critical facts known |
Primary blocker: uncertain event
Why this action
Technical
- 0.8% below the trigger 264.79 (resistance 264.53)
- RS20 positive vs one benchmark (+1.5% / -3.4%)
- EMA20 extension 0.20 ATR
- RSI14 53.7 inside the 50-70 band
- stop 259.38: 1 ATR below the breakout level 264.53
- a high-materiality event with unknown direction converts the entry to WAIT
- RS20 vs SPY 1.5%, vs QQQ -3.4%
Options
- volume 2.44× the 20D baseline (neither) · selected contracts only, delayed
News and events
- news context positive w/ risks (82 canonical items in window)
- high-materiality item with unknown direction
- earnings 2026-10-30 (19 sessions, finnhub); event risk low
- fda · high · unknown: AbbVie Presents Data From Its Current Phase 3 Viti-Up-1, Viti-Up-2 Trials Of RINVOQ At 202
- fda · high · positive: AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstra
- fda · high · positive: Abbvie Shared Detailed Results From The Multiple Ascending Dose Part Of Its Phase 1 Study
- fda · high · positive: AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in M
Market and risk
- regime RISK ON: SPY: trend UP, volatility NORMAL; QQQ: trend UP, volatility NORMAL
- gate uncertain event blocks a new entry
Chart
Indicator history is derived from the stored bars with the accepted M3 functions (WORKSTATION_SERIES_V1); the scanner’s persisted values remain authoritative. Reconciliation at the scan session: 8 match.
Trade priority
Rank #9 · priority 78.4 / 100 · coverage 100%
- technical readiness28/30
- structure quality6/10
- relative strength7/15
- participation10/10
- risk reward11/15
- news context6/10
- event risk5/5
- urgency5/5
operational attention priority not a return forecast. Missing inputs lower coverage, never the score.
Setup evidence · PRE_BREAKOUT_V1
- Setup state
- PRE_BREAKOUT
- Resistance
- 264.53
- Distance
- 0.65%
- Close
- 262.82
- SMA50
- 257.84
- SMA150 / SMA200
- 233.95 / 231.52
- RSI14
- 53.7
- EMA20 extension
- 0.2 ATR
- RS20 vs SPY
- +1.5%
- RS20 vs QQQ
- -3.4%
Hard requirements · 8/8 passed
- PASSConfirmed resistanceresistance=264.53 exists eligible=true
- PASSDistance to resistancedistance_pct=0.6464 · resistance=264.53 · close=262.82 inclusive_between min=0 · max=3
- PASSClose above SMA50close=262.82 · sma50=257.8426 > right_operand=sma50
- PASSSMA150 ≥ SMA200sma150=233.9478 · sma200=231.5172 >= right_operand=sma200
- PASSRSI14 bandrsi14=53.7359 inclusive_between min=50 · max=70
- PASSEMA20 extension (ATR)extension_atr=0.2004 · close=262.82 · ema20=261.7871 · atr14=5.1545 <= max=1.5
- PASSRS20 vs SPY or QQQSPY=0.0146 · QQQ=-0.0344 OR > SPY=0 · QQQ=0
- PASSResistance qualitydistinct_touches=2 policy_and_minimum_touches min=2
Supporting evidence · 3/6 passed
- PASSATR compressioncurrent_atr_pct=0.0196 · median_previous_60_atr_pct=0.0232 · ratio=0.847 < right_operand=median_previous_60_atr_pct
- FAILVolume contractionrecent_volume=4,515,637.9136 · baseline_volume=4,074,887.1482 · ratio=1.1082 < max=0.85
- FAILHigher lowslow_1=241.2 · low_2=252.33 · low_3=246.7701 low_3 > low_2 > low_1 required_pivots=3
- PASSFull MA alignmentsma50=257.8426 · sma150=233.9478 · sma200=231.5172 sma50 > sma150 > sma200
- PASSRS20 vs SPY positiveSPY=0.0146 > min=0
- FAILRS20 vs QQQ positiveQQQ=-0.0344 > min=0
PRE_BREAKOUT_V1 · scan run 410 · session 2026-10-02 · evaluated as of 2026-10-04T13:22:30.123326Z. Supporting evidence never changes the trigger; UNKNOWN is never collapsed into false.
Intelligence timeline
- 2026-10-0402:46 UTCAbbVie Inc. (NYSE:ABBV) closed at $262.82 on October 2, and Bristol Myers Squibb Company (NYSE:BMY) at $61.15. Both spent the last few years doing the same difficult thing. Replacing a drug that was about to lose its patent with something new, before the revenue disappeared. AbbVie is widely seen as having pulled it off and […]
- 2026-10-0310:10 UTCAnother potential blockbuster just joined AbbVie's drug portfolio.
- 2026-10-0221:00 UTC
- 2026-10-0215:59 UTChttps://news.abbvie.com/2026-10-02-AbbVie-to-Participate-in-Federal-340B-Rebate-Model-Pilot
- 2026-10-0212:30 UTCJNJ's Innovative Medicine segment is poised for another quarter of growth, with oncology and new launches helping offset Stelara's biosimilar-driven decline.
- 2026-10-0122:41 UTCAbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.
- 2026-10-0122:13 UTCJNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.
- 2026-10-0117:12 UTCAbbVie has delivered a powerful 187.5% total return over the past 5 years, so the current US$261.59 share price naturally raises a question for investors who care about cash generation. With fresh drug approvals, pipeline updates and new partnerships in the headlines, the key issue now is whether AbbVie’s cash flows are strong enough and durable enough to underpin where the stock trades today. Tha
- 2026-10-0115:41 UTCEli Lilly (LLY) management said on its second-quarter 2026 call that the price of Zepbound, its obesity drug, will go down. The company's sales growth rests on two drugs whose prices are falling - Zepbound and Mounjaro. That makes it difficult to call the stock's coming twelve months. So how do you really understand the risk you are taking with Eli Lilly stock? Well, you can look at the options ma
- 2026-10-0114:00 UTCAbbVie (NYSE: ABBV) today announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ® (upadacitinib; 15 mg once daily) in non-segmental vitiligo (NSV), showing continued facial and total body repigmentation through week 76.
- 2026-10-0112:00 UTCAbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 2026-10-0112:00 UTCAbbVie (NYSE: ABBV) will announce its third-quarter 2026 financial results on Friday, October 30, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
- 2026-10-0110:04 UTCAbbVie (NYSE: ABBV) today announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ® (upadacitinib; 15 mg once daily) in non-segmental vitiligo (NSV), showing continued facial
- 2026-09-3016:50 UTCThe pharmaceutical giant still looks like a stable long-term investment.
- 2026-09-3015:35 UTCAbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.
- 2026-09-3015:29 UTCPfizer's shares cost more than Johnson & Johnson's for each dollar of reported profit, even after factoring in a loss quarter over the past year. Investors usually pay more for growth, yet Pfizer (PFE) had the weakest sales growth of the six companies in its peer group. Are you overpaying for Pfizer stock versus its rivals.
- 2026-09-3015:10 UTCAbbVie (NYSE: ABBV) reported Phase 2 APEX Part B data for zumilokibart in moderate to severe atopic dermatitis at the EADV Congress. The company selected a mid dose of zumilokibart for Phase 3 development after the study showed significant clinical improvements in patients. AbbVie joined the Antibody Developability Consortium as a founding member and started a new AI driven R&D collaboration with
- 2026-09-3014:18 UTCA former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.
- 2026-09-3013:40 UTCAI-driven discovery, streamlined approvals and partnerships are accelerating drug repurposing, creating opportunities in oncology, rare, neurodegenerative and infectious diseases.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Drug Repurposing Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global drug repurposing market was valued at US$29.4 billion
- 2026-09-3010:49 UTCAbbVie Inc. (NYSE:ABBV) announced clinical trial data on Wednesday for two pipeline candidates, highlighting progress in its immunology and metabolic disease portfolios. The pharma giant shared encouraging Phase 2
- 2026-09-3009:45 UTCAbbVie (NYSE: ABBV) today announced that detailed results from the multiple ascending dose (MAD) part of its Phase 1 study evaluating ABBV-295 will be presented in a short oral presentation at the European Association for the Study of Diabetes (EASD) 2026 Annual Meeting (Milan, Italy; September 28 – October 2). The study evaluated the tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)
- 2026-09-3008:07 UTCCNBC traders picked Eaton, SpaceX, AbbVie and AMD, citing analyst support, SpaceX’s Starship launch and AbbVie’s FDA drug approval.
- 2026-09-3005:57 UTCAbbVie (NYSE:ABBV) today announced that detailed results from the multiple ascending dose (MAD) part of its Phase 1 study evaluating ABBV-295 will be presented in a short oral presentation at the European Association
- 2026-09-3005:30 UTCAbbVie (NYSE: ABBV) today announced that the primary results from the ongoing Phase 2 APEX Part B Dose-Regimen-Finding Study, evaluating zumilokibart, in adult patients with moderate to severe atopic dermatitis (AD) will be presented as a late-breaker presentation at the 2026 Annual European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Sept. 30 – Oct. 3.
- 2026-09-3005:00 UTCAbbVie (NYSE: ABBV) today announced new research across its diverse dermatology portfolio to be presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, September 30 – October 3 in Vienna, Austria. The breadth of data from 60 abstracts, including three late-breaking presentations, reflects AbbVie's expanding portfolio across a wide spectrum of immune-mediated skin dis
- 2026-09-3002:54 UTCPhase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater improvements in Eczema Area and Severity Index -75 (EASI-75) response
- 2026-09-2920:45 UTCAbbVie (ABBV) closed the most recent trading day at $263.29, moving 1.12% from the previous trading session.
- 2026-09-2918:57 UTCSeveral members of the elite Dividend Kings club, including JNJ, KO, and ABBV, are known for dividend reliability, each with a long, consistent history of increasing payouts. The trio boasts a strong defensive nature given consumers' needs for their products no matter the backdrop.
- 2026-09-2918:30 UTCAbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.84% on an annualized basis producing an average annual return of 15.37%. Currently, AbbVie has a market capitalization of $465.70 billion.
- 2026-09-2916:19 UTCThe once-daily treatment reaches the U.S. market in October after improving motor-control measures across three Phase 3 studies.
- 2026-09-2913:00 UTCAbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation reaches patients.
- 2026-09-2912:00 UTCBOSTON, September 29, 2026--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
- 2026-09-2910:41 UTCCNBC’s final trades: Weiss picked UnitedHealth, Lebenthal chose AbbVie after FDA approval, and Terranova backed Okta amid raised price targets.
- 2026-09-2909:08 UTCAbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation
- 2026-09-2906:23 UTCGOOGL, MA and ABBV headline today's research, with AI-led growth, electronic payments and strong drug portfolios shaping their outlooks.
- 2026-09-2819:49 UTCAlphabet's AI-led cycle is strengthening Search, Cloud and subscriptions, while rising investment and regulatory risks create uncertainty around returns.
- 2026-09-2819:39 UTCADARx Pharmaceuticals is testing investor appetite for another biotech listing, targeting a valuation of as much as $1.74 billion in a U.S. IPO that could raise up to $371.9 million. The San Diego-based RNA drug developer plans to offer 21.9 million shares at between $15 and $17 apiece and list on the Nasdaq under the […]
- 2026-09-2815:14 UTCKey Stats for AbbVie StockCurrent Price: $264. 34Target Price (Mid): ~$363Street Target: ~$279Potential Total Return: ~37%Annualized IRR: ~8% / yearWhat Happened?The FDA approved Juvmo (tavapadon), a once-daily Parkinson’s pill from AbbVie (ABBV), on Friday, September 25, according to Reuters.
- 2026-09-2813:38 UTCFDA approves AbbVie's Juvmo for Parkinson's disease, the first D1/D5 agonist. U.S. launch set for Oct 2026. Get pricing and sales data.
- 2026-09-2808:02 UTCAbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with
- 2026-09-2720:28 UTCAbbVie Inc. (NYSE:ABBV) and Iambic announced a multi-year collaboration to use Iambic’s AI platform to accelerate small-molecule drug discovery across immunology, neuroscience, and oncology. The partnership will use Iambic’s Enchant v3 model, which is trained on more than 6,000 molecular properties and is designed to evaluate multiple drug characteristics simultaneously. The companies will pursue
- 2026-09-2616:12 UTCAbbVie (NYSE:ABBV) acquired a stake in ADARx Pharmaceuticals during its IPO, gaining exposure to RNA interference drug candidates. The investment in ADARx ties AbbVie to RNA-based therapies being developed for certain rare disease indications. Health Canada granted marketing authorization for AbbVie's EPKINLY for adults with relapsed or refractory follicular lymphoma. AbbVie's move into ADARx's IP
- 2026-09-2523:16 UTCAbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.
- 2026-09-2521:22 UTCAbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.
- 2026-09-2515:01 UTCAbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balance sheet that could force retirees to rethink their income strategy completely.
- 2026-09-0312:47 UTC
- hidden37 provider-tagged items never name the company and are kept as context only.
canonical items of the last 10 sessions; analyst/industry/macro commentary and social sources excluded from the direction tally; gating uses tier 1-3 HIGH items within 3 (negative) / 2 (unknown direction) sessions
Catalysts and filings
| Event | Date | In | Materiality | Source |
|---|---|---|---|---|
| Earnings | 2026-10-30 | 19 sessions | high | finnhub · Tier 3 · provider |
Options activity
- Session volume
- 2,252
- 5D baseline
- 1,084
- 20D baseline
- 924
- Volume / 20D
- 2.44x
- Call / put volume
- 1,818 / 434
- Call / put ratio
- 4.19
- Top-3 contract share
- 46%
- Top expiration
- 2026-10-09 83%
Activity trend · last 34 sessions
| Session | Volume | 5D | 20D | / 20D |
|---|---|---|---|---|
| 2026-09-28 | 1,455 | 1,253 | 797 | 1.83x |
| 2026-09-29 | 1,017 | 1,109 | 853 | 1.19x |
| 2026-09-30 | 981 | 1,117 | 883 | 1.11x |
| 2026-10-01 | 1,202 | 1,010 | 895 | 1.34x |
| 2026-10-02 | 2,252 | 1,084 | 924 | 2.44x |
Call vs put volume
Expiration concentration
Contract concentration
Top contracts · session 2026-10-02
| Contract | Type | Strike | Expiration | DTE | Volume | 5D avg | 20D avg | / 20D | Return | Moneyness |
|---|---|---|---|---|---|---|---|---|---|---|
| O:ABBV261009C00262500 | CALL | 262.5 | 2026-10-09 | 7 | 470 | 4 | insufficient history | insufficient history | 44.6% | ATM (0.1%) |
| O:ABBV261009C00265000 | CALL | 265 | 2026-10-09 | 7 | 303 | 28 | 31 | 9.85x | 122.2% | OTM (-0.8%) |
| O:ABBV261009C00270000 | CALL | 270 | 2026-10-09 | 7 | 264 | 117 | 105 | 2.50x | 31.3% | OTM (-2.7%) |
| O:ABBV261016C00270000 | CALL | 270 | 2026-10-16 | 14 | 144 | 238 | 200 | 0.72x | 31.4% | OTM (-2.7%) |
| O:ABBV261009C00275000 | CALL | 275 | 2026-10-09 | 7 | 126 | 60 | 22 | 5.65x | 35.5% | OTM (-4.4%) |
| O:ABBV261009C00272500 | CALL | 272.5 | 2026-10-09 | 7 | 116 | 70 | insufficient history | insufficient history | 77.8% | OTM (-3.6%) |
| O:ABBV261009P00257500 | PUT | 257.5 | 2026-10-09 | 7 | 115 | 14 | insufficient history | insufficient history | -41.3% | OTM (2.1%) |
| O:ABBV261009C00267500 | CALL | 267.5 | 2026-10-09 | 7 | 104 | 91 | insufficient history | insufficient history | 60.9% | OTM (-1.7%) |
| O:ABBV261009P00252500 | PUT | 252.5 | 2026-10-09 | 7 | 85 | insufficient history | insufficient history | insufficient history | -51.2% | OTM (4.1%) |
| O:ABBV261009C00260000 | CALL | 260 | 2026-10-09 | 7 | 71 | 3 | insufficient history | insufficient history | 50.3% | ITM (1.1%) |
| O:ABBV261009P00260000 | PUT | 260 | 2026-10-09 | 7 | 67 | 48 | insufficient history | insufficient history | -48.0% | OTM (1.1%) |
| O:ABBV261016C00260000 | CALL | 260 | 2026-10-16 | 14 | 46 | 44 | 130 | 0.35x | 75.8% | ITM (1.1%) |
| O:ABBV261009P00255000 | PUT | 255 | 2026-10-09 | 7 | 45 | 76 | insufficient history | insufficient history | -64.3% | OTM (3.1%) |
| O:ABBV261009P00262500 | PUT | 262.5 | 2026-10-09 | 7 | 40 | 19 | insufficient history | insufficient history | -38.5% | ATM (0.1%) |
| O:ABBV261016C00265000 | CALL | 265 | 2026-10-16 | 14 | 37 | 20 | insufficient history | insufficient history | 35.7% | OTM (-0.8%) |
OPTIONS_SELECTION_M9_V1 selected contracts only · provider capability DELAYED · delayed · Top 15 selected contracts by session volume; 5D/20D averages use strictly prior sessions (M10), INSUFFICIENT_HISTORY is shown, never zero.
M13 observations for this session
- Technical setup present (PRE_BREAKOUT_V1): TRUE
- Technical and options context share a session: TRUE
- Activity above its own 20-session baseline: TRUE
- Activity below its own 20-session baseline: FALSE
- Recent 5-session baseline above 20-session baseline: FALSE
- Recent 5-session baseline below 20-session baseline: FALSE
- Volume concentrated in top 3 contracts: FALSE
- Volume concentrated in one expiration: TRUE
- Calls carry most session volume: TRUE
- Puts carry most session volume: FALSE
- Call and put volume roughly balanced: FALSE
- Enrichment data (snapshot/OI/IV/Greeks) available: FALSE
- Enrichment data unavailable: TRUE
- Real flow data unavailable: TRUE
- Flow events present in replay window: NOT_EVALUABLE
Flow
Flow engine is ready. Trades and Quotes are not available with the current provider capabilities; this area populates automatically from the same M11 engine when real persisted facts exist. Synthetic fixture flow is never shown.
Evidence alerts
| Category | Alert | Previous | Current | Sessions | Workflow | Actions |
|---|---|---|---|---|---|---|
| New | New technical setup (PRE_BREAKOUT_V1 appeared) | no | yes | 2026-10-01 → 2026-10-02 | New | |
| Changed | Options activity vs 20D baseline rose | 1.34 | 2.44 | 2026-10-01 → 2026-10-02 | New | |
| Changed | Top expiration concentration increased | 0.69 | 0.83 | 2026-10-01 → 2026-10-02 | New |
Decision trace
- setup_eligiblePASSPRE_BREAKOUT_V1 on 2026-10-02: all 8 hard conditions passresistance=264.53 · close=262.82 · distance_pct=0.6464295165009564
- trigger_statePASSNOT_TRIGGERED; trigger 264.79 is 0.38 ATR above the close (within 1 ATR)trigger_price=264.79 · distance_to_trigger_atr=0.38 | threshold near_trigger_atr=1
- data_freshnessPASS0 completed session(s) behind the calendarsessions_behind=0 | threshold max_sessions_behind=1
- price_gatePASSclose 262.82 at or above the 10 floorclose=262.82 | threshold min_price=10
- market_cap_gatePASSmarket cap 459.33B (finnhub, 2026-10-02)market_cap_usd=459326795846.18 | threshold min_market_cap_usd=1000000000
- liquidity_gatePASSADV20 1115.8M (STRONG_LIQUIDITY)adv_dollar=1115812806.17 · strong_liquidity=true | threshold min_adv_dollar=25000000, strong_adv_dollar=50000000
- sector_gatePASSsector Healthcare (finnhub_industry)
- market_regime_gatePASSregime RISK_ONregime=RISK_ON · risk_multiplier=1
- event_risk_gatePASSearnings in 19 sessions (2026-10-30)earnings_sessions_away=19 | threshold earnings_block_sessions=5
- news_gateFAILHIGH-materiality event with unknown direction
- chase_gatePASS0.20 ATR above EMA20, session move 0.56 ATRextension_atr=0.2 | threshold breakout_max_extension_atr=2
- risk_rewardPASSreward/risk 2.81 to target 1 (strong), 4.72 to target 2reward_risk_1=2.81 · reward_risk_2=4.72 | threshold min_reward_risk_1=2
- portfolio_gatePASS1 shares (265), bound by risk budgetshares=1 · risk_amount=5.41 · regime_multiplier=1 · share_increment=1
- data_qualityPASScurrent session data, valid technical snapshot, trigger and ATR; critical facts known
- finalPASSWAIT (blocked by MATERIAL_UNCERTAINTY; primary MATERIAL_UNCERTAINTY)
Snapshot history: 2026-10-02 WAIT · 2026-09-30 WAIT
Actions are generated from the configured trading strategy and current available market/intelligence data. They are not guarantees of future performance.